Clinical trials: Intestine
Colorectal Neoplasms
Randomized Study Of Sunitinib Plus FOLFOX Versus Bevacizumab Plus FOLFOX In Metastatic Colorectal Cancer
This study will compare the safety and efficacy of sunitinib in combination with FOLFOX versus bevacizumab in combination with FOLFOX for the treatment of patients with metastatic colorectal cancer who have not been treated…
- Trial name
- NCT00609622
- Testing
- sunitinib, mFOLFOX6, bevacizumab
- Where
- 97 sites in United States, Denmark and 2 more
- Volunteers
- 191 people
- Sponsor
- Pfizer
Crohn Disease
Open-label Trial of Leukine in Active Crohn's Disease
The purpose of this study is to establish a safety profile sargramostim administered in 8 week cycles to adult patients with active Crohn's disease.
- Trial name
- NCT00206700
- Testing
- Sargramostim (Leukine)
- Where
- 167 sites in United States, Argentina and 8 more
- Volunteers
- 378 people
- Sponsor
- Genzyme, a Sanofi Company
Infant ALL
A Clinical Trial on the Effect of Infant Formula Consumption on Growth, Immune Parameters, and Gut Health in Healthy Term Infants
The goal of this clinical trial is to study growth (weight gain per day) in healthy full-term infants who consume the investigational infant formula containing beneficial ingredients against infants consuming a control infant…
- Trial name
- NCT07867509
- Testing
- Infant Formula, Breastfeeding
- Volunteers
- 387 people, healthy volunteers welcome
- Sponsor
- FrieslandCampina
Colitis, Hepatitis
PHOENIX-ECP- Extracorporeal Photopheresis for Immune-related Colitis and/or Hepatitis in Advanced Melanoma With Inadequate Response to Steroid Exposure
Extracorporeal photopheresis (ECP) is an immunomodulatory therapy in which the photoactivating agent methoxsalen (also known as UVADEX) is used in combination with ultraviolet A (UVA) light.
- Conditions
- Colitis, Hepatitis, Melanoma (Skin Cancer)
- Trial name
- PHOENIX-ECP (NCT07619898)
- Testing
- methoxsalen, Extracorporeal photopheresis (ECP), Vedolizumab
- Volunteers
- 112 people
- Sponsor
- Therakos LLC
Crohn´s Disease
A Study With Pentasa in Patients With Active Crohn's Disease
The purpose of this trial is to demonstrate that Pentasa administered as a 2 g morning dose and a 4 g evening dose is efficacious in active mild to moderate CD.
- Trial name
- PEACE (NCT00862121)
- Testing
- Pentasa
- Where
- 15 sites in United States, Belgium and 5 more
- Volunteers
- 20 people
- Sponsor
- Ferring Pharmaceuticals
Healthy
A Clinical Study to Assess the Effect of Novel Glycans on Nitrogen Metabolism of the Gut in Healthy Subjects
This exploratory, randomized, double-blind, placebo-controlled study aims to explore the effect of novel glycans on nitrogen metabolism in the gut in healthy subjects using a stable isotope.
- Trial name
- NCT04603378
- Testing
- KB195, Polydextrose, Pullulan
- Where
- United States
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- Kaleido Biosciences
Metastatic Sarcoma, Esophageal Cancer
64Cu-LNTH-1363S in Patients With Sarcoma or Gastrointestinal Tract Cancer
This is a multicenter, open-label, prospective Phase 1/2a study to assess safety and tolerability, establish dosimetry and to identify an optimal imaging dose (radioactivity) and imaging time window of 64Cu-LNTH-1363S, and to…
- Conditions
- Metastatic Sarcoma, Esophageal Cancer, Gastric Cancer, Pancreatic Cancer
- Trial name
- PHANTOM (NCT06298916)
- Testing
- 64Cu-LNTH-1363S
- Where
- 5 sites in United States
- Volunteers
- 26 people
- Sponsor
- Lantheus Medical Imaging
Solid Tumor, Colorectal Cancer
A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors
The main purpose of this study is to establish the safety and the recommended dose of TRK-950 in combination with FOLFIRI, Gemcitabine / Cisplatin, Gemcitabine / Carboplatin, Ramucirumab / Paclitaxel, PD1 inhibitors (Nivolumab or…
- Conditions
- Solid Tumor, Colorectal Cancer, Cholangiocarcinoma, Bladder Cancer
- Trial name
- NCT03872947
- Testing
- TRK-950, Irinotecan, Leucovorin
- Where
- 14 sites in United States, France
- Volunteers
- 138 people
- Sponsor
- Toray Industries, Inc
Colorectal Neoplasms
Stivarga Regulatory Post-Marketing Surveillance Study in Korea
To investigate and collect post-marketing data on the safety of Stivarga in real world practice in its registered indication(s) as required by Health Authority.
- Trial name
- StivargaPMS (NCT02106858)
- Testing
- Regorafenib (Stivarga,BAY73-4506)
- Where
- South Korea
- Volunteers
- 316 people
- Sponsor
- Bayer
Crohn's Disease
Postmarketing Safety Surveillance European Registry of Crohn's Disease Patients Treated With Remicade or Standard Therapy (MK-2155-035)
Prospective, observational, parallel-group, postmarketing safety surveillance registry in participants treated with Remicade or standard therapy for active or fistulizing Crohn's disease (CD).
- Trial name
- ENCORE (NCT00705614)
- Testing
- Remicade
- Volunteers
- 2,662 people
- Sponsor
- Merck Sharp & Dohme LLC
Solid Tumor, Lung Cancer
Safety and Efficacy of CEA-Targeted CAR-T Therapy for Relapsed/Refractory CEA+ Cancer
This is a single arm study to evaluate the efficacy and safety of CEA-targeted CAR-T cells therapy for patients with relapsed/refractory CEA+ Cancer,and obtain the recommended dose and infusion plan.
- Conditions
- Solid Tumor, Lung Cancer, Colorectal Cancer, Liver Cancer
- Trial name
- NCT04348643
- Testing
- CEA CAR-T cells
- Where
- 2 sites in China
- Sponsor
- Chongqing Precision Biotech Co., Ltd
Melanoma, Prostate Cancer
An Expanded Access Program for AM0010 (Pegilodecakin)
This is an Expanded Access Program (EAP) available to patients who have advanced cancers, who have failed or progressed on standard of care systemic therapy and do not qualify for ongoing clinical trials.
- Conditions
- Melanoma, Prostate Cancer, Ovarian Cancer, Renal Cell Carcinoma
- Trial name
- NCT03554434
- Testing
- AM0010
- Sponsor
- Eli Lilly and Company
Colorectal Cancer, Gastric Cancer
Study of Intratumoral IVX037 in Patients With Advanced or Metastatic Solid Tumours
This is a Phase 1 open-label, non-randomized, multi-center clinical trial of intratumoral IVX037 as monotherapy and in combination with an immune checkpoint inhibitor in patients with advanced micro satellite-stable (MSS)…
- Conditions
- Colorectal Cancer, Gastric Cancer, Ovarian Cancer
- Trial name
- NCT05427487
- Testing
- IVX037, Sintilimab
- Where
- 3 sites in Australia
- Volunteers
- 70 people
- Sponsor
- ImmVirx Pty Ltd
Fecal Incontinence
Long Term Safety and Efficacy of Solesta® Injectable Bulking Agent for the Treatment of Fecal Incontinence (SoFI)
The purpose of this observational study is to evaluate the safety and effectiveness of the Solesta Injectable Bulking Agent in the treatment of fecal incontinence through 3 years in a real world setting.
- Trial name
- SoFI (NCT01647906)
- Where
- 20 sites in United States
- Volunteers
- 277 people
- Sponsor
- Bausch Health Americas, Inc.
Non-small Cell Lung Cancer, Gastric Cancer
A Study of CDX-585 in Patients With Advanced Malignancies
This is an open-label, non-randomized, multicenter, dose-escalation and expansion study in patients with selected solid tumors.
- Conditions
- Non-small Cell Lung Cancer, Gastric Cancer, Head and Neck Cancer, Ovarian Cancer
- Trial name
- NCT05788484
- Testing
- CDX-585
- Where
- 4 sites in United States
- Volunteers
- 20 people
- Sponsor
- Celldex Therapeutics
Crohn's Disease
Study To Evaluate The Efficacy And Safety Of Oral PF-06651600 And PF-06700841 In Subjects With Moderate To Severe Crohn's Disease
The objectives of this study are to evaluate the efficacy, safety, tolerability, pharmacokinetics, and pharmacodynamics of PF-06651600 (200 mg for 8 weeks followed by 50 mg for 4 weeks) dosed once daily and PF-06700841 (60 mg for…
- Trial name
- NCT03395184
- Testing
- PF-06651600, PF-06700841
- Where
- 195 sites in United States, Australia and 24 more
- Volunteers
- 244 people
- Sponsor
- Pfizer
Colorectal Cancer
Performance of NER1008 Enema Compared With Fleet® Enema in Bowel Cleansing
In order for flexible sigmoidoscopy to be a successful screening procedure, the bowel must be free of solid matter so the endoscopist has a clear view, increasing the chance of detection of abnormalities.
- Trial name
- NCT02468726
- Testing
- NER1008 enema, Fleet
- Where
- United Kingdom
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Norgine
Crohn's Disease
A Study to Evaluate the Efficacy and Safety of CCX282-B in Subjects With Moderate to Severe Crohn's Disease
The purpose of this study is to determine whether CCX282-B is effective in treating patients with moderate to severe Crohn's Disease.
- Trial name
- NCT00306215
- Testing
- CCX282-B
- Where
- 112 sites in Australia, Austria and 15 more
- Volunteers
- 436 people
- Sponsor
- Amgen
HSIL, High-Grade Squamous Intraepithelial Lesions, Human Papilloma Virus Infection
Study of Topical ABI-1968 in Subjects With Precancerous Anal Lesions Resulting From Human Papillomavirus (HPV) Infection
This study evaluates the use of ABI-1968, a topical cream, in the treatment of anal precancerous lesions in adults with and without human immunodeficiency virus (HIV) infection.
- Conditions
- HSIL, High-Grade Squamous Intraepithelial Lesions, Human Papilloma Virus Infection, HIV Infection, Anal Cancer
- Trial name
- NCT03202992
- Testing
- ABI-1968
- Where
- 6 sites in United States, Australia
- Volunteers
- 57 people
- Sponsor
- Antiva Biosciences
Part 1: Bladder, Biliary Tract, Cervical, Endometrial, Ovarian, Pancreatic Cancer, Rare Tumors, Any Tumor Type Excluding Breast, Gastric, Colorectal Cancer, Part 2: HER2 Expressing/Amplified Solid Tumors Excluding Breast, Gastric, Colorectal Cancer
A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors
This is an open-label, multi-center, multi-cohort, Phase 2 study to evaluate the efficacy and safety of trastuzumab deruxtecan (T-DXd) for the treatment of selected HER2-expressing tumors.
- Trial name
- DPT02 (NCT04482309)
- Testing
- Trastuzumab deruxtecan
- Where
- 89 sites in United States, Australia and 15 more
- Volunteers
- 477 people
- Sponsor
- AstraZeneca